CSIMarket Company Name, Ticker, Competitors, else..
 
Celcuity Inc   (NASDAQ: CELC)
Other Ticker:  
 
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 
Price: $12.6100 $-0.24 -1.868%
Day's High: $12.92 Week Perf: -4.11 %
Day's Low: $ 12.43 30 Day Perf: -22.4 %
Volume (M): 232 52 Wk High: $ 22.19
Volume (M$): $ 2,922 52 Wk Avg: $15.94
Open: $12.80 52 Wk Low: $11.51



 Market Capitalization (Millions $) 485
 Shares Outstanding (Millions) 38
 Employees 58
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -86
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 0

Celcuity Inc
Celcuity Inc is a biotechnology company that focuses on developing targeted therapeutics for the treatment of cancer. The company specializes in identifying and analyzing unique cellular signaling signatures found in patients' tumor cells. By understanding these signatures, Celcuity aims to develop personalized therapies that target specific molecular pathways and improve patient outcomes. The company utilizes its proprietary CELsignia platform to analyze tumor cells and identify potential therapeutic targets. Celcuity's ultimate goal is to revolutionize cancer treatment by advancing precision medicine and providing patients with more effective and personalized therapies.


   Company Address: 16305 36th Minneapolis 55446 MN
   Company Phone Number: 392-0767   Stock Exchange / Ticker: NASDAQ CELC


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
APRE      % 
CPRX   -3.09%    
IOVA   -11.85%    
SMLR        13.48% 
ZYME   -11.44%    
• View Complete Report
   



Shares

Celcuity Inc. Announces Pricing of Stock Offering for Oncology Development, Share Price Drops

Published Thu, May 30 2024 11:36 AM UTC


Celcuity Inc., a clinical-stage biotechnology company focused on targeted therapies for oncology, recently revealed the pricing of their underwritten common stock offering. The offering includes 3,871,000 shares of common stock at a price of $15.50 per share. All of the securities are being sold by Celcuity, with several notable investors, such as BVF Partners L.P., Viv...
Clinical Study

Advancing the Frontiers of Breast Cancer Treatment: Celcuitys Phase 3 Clinical Trial f...

Published Thu, May 30 2024 11:00 AM UTC

Celcuity Inc., a pioneering clinical-stage biotechnology company specializing in the development of targeted therapies for oncology, has made a significant announcement that holds immense promise for patients with HR+/HER2- advanced breast cancer (ABC). The company has revealed plans to commence a Phase 3 clinical trial to investigate the efficacy of gedatolisib in combinati...
Clinical Study

Investigating the Efficacy of Gedatolisib in Combination with Nubeqa for Metastatic Castration Resistant Prostate Cancer

Published Thu, Feb 22 2024 9:05 PM UTC

Celcuity Inc., a clinical-stage biotechnology company, has initiated a Phase 1b/2 clinical trial (CELC-G-201) to evaluate the effectiveness of gedatolisib in combination with Nubeqa for the treatment of metastatic castration resistant prostate cancer (mCRPC). Gedatolisib, Celcuity's leading therapeutic candidate, is a powerful dual inhibitor that selectively targets all Clas...
Celcuity Inc

Expenses Skyrocket in Q2 2023 as Celcuity Inc Faces Uphill Battle, but Investors Stay Hopeful for Bright Future

During the past five days, Celcuity Inc's stock has experienced a slight increase of 0.81%. While this may appear positive at first glance, it is important to note that the year-to-date performance of the stock is still quite negative, standing at -22.39%. Additionally, the stock is currently trading 32.7% above its 52-week low.
Celcuity Inc, a company in the Medical Laboratories sector, recently reported its earnings for the second quarter of 2023. The company announced an operating loss of $-15.055485 million during this period. While this news may seem discouraging, investors remain optimistic about the future prospects of the company. They anticipate the development of a new business model in the near future, which is expected to drive growth and profitability.
Celcuity Inc

Celcuity Inc's Existing Expenditures Surge in 1Q 2023, Prompting Cautious Investor Approach in Healthcare Sector

Investors may want to exercise caution when considering Celcuity Inc as a potential investment opportunity in the Healthcare sector. The company recorded a cumulative net loss of $-44 million during the 12 months ending in the first quarter of 2023, resulting in a negative return on investment (ROI) of -39.03%. Compared to other companies in the same sector, Celcuity's ROI ranks at 4199, with 568 other companies having a higher ROI.
During the January to March 31 reporting cycle, the company's operating loss was recorded at $-12.547537 million, a significant decline from the first quarter of 2022, when it was recorded at $-7.507605 million. While the market observers are hoping for Celcuity to start reporting revenue, the management is reportedly exploring various business models to ensure the introduction of new product lines.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com